Researchers Invent Cancer Fighting Compound using Hettich EBA 12 Centrifuge
Hans-Ulrich Demuth, Torsten Hoffmann, and Ulrich Heiser invented a new formula compound using glutaminyl-based dipeptidyl peptidase IV (DPIV) inhibitors for the prevention and treatment of cancer and tumors. The Hettich EBA 12 centrifuge was used in the process.
The researchers studied in vivo cell adhesion and growth of syngeneic mammary adenocarcinoma MADB106 in F344 rats after actual and chronic treatment with DPIV-ligands. Both mutant F344 substrains lacking DPIV enzymic activity and wild-type-like F344 were tested.
During experimentation, arterial blood samples were taken from the lab rats and collected into ice cooled tubes filled with 10 ul 1M sodium citrate buffer (pH 3.0) for plasma DPIV activity measurement. The sample tubes were then immediately centrifuged at 12,000 rpm for 2 minutes using a Hettich EBA 12 centrifuge. Findings from the study showed that the metastasis of MADB106 was reduced by treatment using different DPIV inhibitors after two weeks.
The compound, when paired with a pharmaceutically acceptable carrier and/or diluent, not only provides a new method for cancer and tumor treatment, but also treats conditions including arthritis, obesity, immune and autoimmune disorders, allograft transplantation, neuronal disorders and dermal disease.
Hettich provides a wide range of centrifuges for reliable clinical testing and research applications. To find a Hettich centrifuge that fits your application, visit www.hettweb.com/view-all-centrifuges.html.